ZNF852 Antikörper (AA 65-180) (Biotin)
-
- Target Alle ZNF852 Produkte
- ZNF852 (Zinc Finger Protein 852 (ZNF852))
- Bindungsspezifität
- AA 65-180
- Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser ZNF852 Antikörper ist konjugiert mit Biotin
-
Applikation
- ELISA, Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))
- Homologie
- Human
- Aufreinigung
- Purified by Protein A.
- Immunogen
- KLH conjugated synthetic peptide derived from human ZNF852
- Isotyp
- IgG
-
-
- Applikationshinweise
-
IHC-P 1:200-400
IHC-F 1:100-500 - Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Konzentration
- 1 μg/μL
- Buffer
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- Lagerung
- -20 °C
- Informationen zur Lagerung
- Store at -20°C for 12 months.
- Haltbarkeit
- 12 months
-
- Target
- ZNF852 (Zinc Finger Protein 852 (ZNF852))
- Andere Bezeichnung
- ZNF852 (ZNF852 Produkte)
- Synonyme
- zinc finger protein 852 antikoerper, ZNF852 antikoerper
- Hintergrund
-
Synonyms: Putative zinc finger protein 852,
Background: Chromosome 3 is made up of about 214 million bases encoding over 1,100 genes. Notably, there is a chemokine receptor gene cluster and a variety of human cancer related loci on chromosome 3. Particular regions of the chromosome 3 short arm are deleted in many types of cancer cells. Key tumor suppressing genes on chromosome 3 encode apoptosis mediator RASSF1, cell migration regulator HYAL1 and angiogenesis suppressor SEMA3B. Marfan Syndrome, porphyria, von Hippel-Lindau syndrome, osteogenesis imperfecta and Charcot-Marie-Tooth Disease are a few of the numerous genetic diseases associated with chromosome 3. The LOC285346 gene product has been provisionally designated LOC285346 pending further characterization.
-